What Is Trulicity? Dulaglutide Basics and Uses

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide lives in the PlexusDx Education Hub, where we unpack GLP-1 science, weight-management protocols, and the genetic factors behind metabolic decisions. Open the Education Hub

What Trulicity is

Trulicity is Eli Lilly's brand of dulaglutide, a once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes in 2014, with a cardiovascular indication added in 2020. Structurally, dulaglutide is a fusion protein that links GLP-1 sequences to a modified IgG4 Fc fragment, a design that helps it persist in the body for weekly dosing. This overview covers its uses, mechanism, side effects, and cost as of April 2026. Open the Education Hub.

What it is approved to treat

Trulicity is FDA-approved for type 2 diabetes, and since 2020 it carries a cardiovascular risk-reduction indication in that population. Notably, it is not FDA-approved for chronic weight management; that distinction belongs to Wegovy, Saxenda, and Zepbound. As with the rest of the class, prescribing follows the brand's specific FDA-approved indication, and the same molecule under a different brand is not automatically interchangeable for coverage.

How it works

Trulicity engages the GLP-1 receptor in the pancreas, hypothalamus, and gastrointestinal tract, slowing gastric emptying, blunting post-meal glucose excursions, reducing appetite, and increasing satiety signaling. GIP/GLP-1 dual agonists such as tirzepatide additionally engage the GIP receptor for a second incretin mechanism. Weekly dosing delivers sustained receptor engagement, and effects on weight and A1C vary by compound and dose according to clinical trial data.

Common side effects

Gastrointestinal symptoms, including nausea, vomiting, diarrhea, and constipation, are the most commonly reported effects and are usually most pronounced during dose titration. All FDA-approved GLP-1 compounds carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Rare serious events include pancreatitis, gallbladder disease, and acute kidney injury in the context of dehydration. As with the rest of the class, these considerations are reviewed by a provider against your personal and family history before any prescription is written.

Cost and access

Manufacturer list prices for FDA-approved branded products typically run $800 to $1,600 per month at U.S. list as of April 2026. Out-of-pocket cost depends on insurance coverage, the FDA indication on the prescription, manufacturer savings card eligibility, and whether a compounded alternative is available through a licensed 503A pharmacy pathway. Coverage for a diabetes indication can differ substantially from coverage tied to weight management, so it is worth confirming both your plan's rules and the indication on your prescription before assuming a given price applies to you.

How Trulicity compares within the class

Placing Trulicity alongside its peers helps clarify where it fits. It is a GLP-1-only agonist, meaning it engages a single incretin receptor, whereas GIP/GLP-1 dual agonists such as tirzepatide add a second mechanism. Its approvals also set it apart: type 2 diabetes and cardiovascular risk reduction, but not chronic weight management, which belongs to Wegovy, Saxenda, and Zepbound. Structurally, the fusion-protein design supports once-weekly dosing, a convenience many patients value. None of this makes one compound universally superior to another, because the right choice depends on the indication a provider is treating and the individual's clinical picture. The broader point is that the class is not interchangeable: mechanism, approved indication, and structure all differ, and those differences drive both prescribing decisions and coverage. Understanding them helps you ask sharper questions when you talk with a provider.

The genetic architecture beneath any GLP-1 choice

PlexusDx does not sell, distribute, or prescribe Trulicity or any therapeutic peptide beyond the semaglutide and tirzepatide products in its Weight Management Protocols. Whichever compound you and your provider discuss, the genetic terrain is the same. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline appetite and energy balance. It does not predict response to any medication.

Frequently Asked Questions

Is Trulicity approved for weight loss?

No. Trulicity (dulaglutide) is FDA-approved for type 2 diabetes, approved in 2014, with a cardiovascular risk-reduction indication added in 2020. It is not FDA-approved for chronic weight management, which is the domain of Wegovy, Saxenda, and Zepbound. Trulicity engages the GLP-1 pathway and is administered per its product label.

How does Trulicity work?

Trulicity engages the GLP-1 receptor to slow gastric emptying, blunt post-meal glucose, reduce appetite, and increase satiety signaling. Weekly dosing sustains that receptor engagement. Effects on weight and A1C vary by compound and dose according to clinical trial data, so your provider tailors the plan to your individual clinical picture.

What is dulaglutide made of?

Dulaglutide is a fusion protein that links GLP-1 sequences to a modified IgG4 Fc fragment. That structure helps the molecule resist rapid breakdown and remain active long enough to support once-weekly dosing. It is the active ingredient in Trulicity, Eli Lilly's brand approved originally for type 2 diabetes.

Can the genetic test predict my Trulicity response?

No. The Precision Peptide Genetic Test does not predict response to Trulicity or any specific medication. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline energy-balance biology, offering upstream context that applies across every GLP-1 pathway compound your provider might discuss.

Keep reading across the PlexusDx Education Hub for more evidence-based GLP-1 and metabolic health explainers. Return to the Education Hub

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.